|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.94 USD | -1.56% |
|
-3.56% | -18.87% |
| Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
| Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
1
Attachments
Disclaimer
Incyte Corporation published this content on 24 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 February 2021 15:24:01 UTC.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.87% | 11.62B | |
| -2.86% | 87.31B | |
| +2.63% | 40.86B | |
| -21.63% | 29.36B | |
| +58.56% | 24.49B | |
| -14.57% | 17.31B | |
| -15.61% | 11.31B | |
| -44.02% | 11.26B | |
| +5.17% | 8.31B | |
| -9.82% | 7.9B |
INCYTE CORPORATION 
